pharma · Hypertension · Gastric Ulcer
Yung Shin Pharmaceutical
Yung NA
Yung NA is a pharma organization headquartered in CN. Primary therapeutic focus areas include Hypertension, Gastric Ulcer, Atrial Fibrillation, Essential Hypertension, Dyslipidemia, Essential Hypertension. NovaPharmaNews
Taichung, CN HQ
1952 Founded
264 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Taichung, CN
- Founded
- 1952
- Employees
- 264
- Programs
- 10
- Drugs
- 13
- Patents
- 0
Prednisone + Jakavi(ruxolitinib)
Phase 2 · small molecule · GVHD - Graft-Versus-Host Disease
Prednisone + Jakavi(ruxolitinib) for GVHD - Graft-Versus-Host Disease is a Phase 2 program (small_molecule) at Yung NA with 1 ClinicalTrials.gov record(s).
Internal code CINC424DKR01T
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Yung NA
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- GVHD - Graft-Versus-Host Disease
- Status
- active
- Trials
- 1